Navigation Links
Amylin Pharmaceuticals to Present Promising Data From Diabetes and Obesity Programs at ADA 2008
Date:6/2/2008

approaches for developing novel, life-changing therapies. This unique approach, paired with our deep expertise in peptide hormones and broad experience in diabetes markets, has allowed us to continue developing important medicines with life-changing therapeutic potential for patients."

KEY AMYLIN ABSTRACTS BEING PRESENTED AT ADA

Diabetes

1. Oral Late Breaker: "Exenatide Once Weekly Elicits Sustained Glycemic

Control and Weight Loss Over 52 Weeks" will be presented by John B.

Buse, M.D., Ph.D., on Monday, June 9 at 5:50 PM PT (8:50 PM ET).

2. Oral: "Exenatide Once Weekly Results in Significantly Greater

Improvements in Glycemic Control Compared to Exenatide Twice Daily in

Patients with Type 2 Diabetes" will be presented by Daniel Drucker,

M.D. on Saturday, June 7 at 9:00 AM PT (12:00 PM ET).

3. Poster: "Exenatide Monotherapy Improves Glycemic Control and is Well

Tolerated Over 24 Weeks in Drug-Naive Patients with Type 2 Diabetes"

will be presented by Robert Brodows, M.D. during a poster session on

Sunday, June 8 from 12:00 - 2:00 PM PT (3:00 - 5:00 PM ET).

4. Oral Late Breaker: "Pramlintide or Mealtime Insulin Added to Basal

Insulin Treatment in Patients with Type 2 Diabetes" will be presented

by Matthew Riddle, M.D. on Monday, June 9 at 4:30 PM PT (7:30 PM ET).

Obesity

1. Poster: "Enhanced Weight Loss Following Pramlintide/Metreleptin

Combination Treatment in Obese Subjects: Clinical Evidence for

Restoration of Leptin Responsiveness by Amylin Agonism" will be

presented by Christian Weyer, M.D. during a poster session on Monday,

June 9 from 12:00 - 2:00 PM PT (3:00 - 5:00 PM ET).

2. Oral: "Enhanced Weight Loss Following Co-Administration of Pramlintide

with Sibutramine or Phentermine in Obese Subjects" will be presented

by Louis Aronne,
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
2. Amylin Pharmaceuticals to Present at FBR Capital Markets Investor Conference
3. Amylin Pharmaceuticals to Present at Baird Growth Stock Conference
4. Amylin Pharmaceuticals to Present at Bank of America Healthcare Conference
5. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
6. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. Amylin Pharmaceuticals to Webcast First Quarter Results
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
10. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
11. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 , Not ... in, into or from any jurisdiction where to do so ... jurisdiction.  Shire plc ("Shire" or the "Company") (LSE: ... this afternoon.  Shire confirms it has held a meeting with ... by Shire without the prior agreement or approval of AbbVie. ...
(Date:7/11/2014)... Research ( http://www.bccresearch.com ) reveals in its new report, ... MARKETS , the global market for digital polymerase chain ... This is estimated to grow to $490 billion in ... of 28.6%. , New digital PCR technology has created ... broader PCR field. The opportunities presented by this technology ...
(Date:7/11/2014)... MISSISSAUGA, ON , July 11, 2014 /CNW/ - ... Canada approved APTIOM TM (eslicarbazepine acetate) for use ... partial-onset seizures in patients with epilepsy who are not ... not indicated for use in patients under 18 years ... the most common neurological disorders and according to Epilepsy ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Cayenne ... company specializing in the soft tissue reconstruction segment, ... Anchor System for surgeries involving the shoulder and ... through a novel, inserter-controlled deployment method. The unique ... partial deployment, anchor pull-out, or anchor displacement (also ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 2Cayenne Medical Launches SureLock™ All-Suture Anchor System for Shoulder and Extremity Surgery 3
... - Neuro-Biotech Corporation (PINKSHEETS: MRES) (OTCQB: MRES) ... in the unique international niche of clinical ... opportunity to market 12 clinical "Neuro Blood ... are without equal in being rapidly done ...
... Inc. (Nasdaq: KERX ) today announced that Ron ... the 2010 UBS Global Life Sciences Conference, being held at ... presentation is scheduled to take place on Wednesday, September 22, ... of Mr. Bentsur,s presentation will be accessible from the Investor ...
... Epitomics, Inc. today announced that The Michael J. ... company to distribute a panel of LRRK2 monoclonal antibodies ... parties. Under a special arrangement the antibodies are being ... community to help advance LRRK2 therapeutic development efforts. The ...
Cached Biology Technology:Neuro-Biotech's Solution for a Doctor near You: Early Detection for Alzheimer's and Chronic Fatigue Syndrome! 2Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference 2Epitomics, Inc. Announces Worldwide Availability of LRRK2 Antibodies Developed in Partnership With The Michael J. Fox Foundation 2
(Date:7/11/2014)... report from the Wildlife Conservation Society shows that ... economically valuable species such as lobster, conch, and ... re-colonize nearby reef areas. , The reporttitled "Review ... review of research literature from no-take areas around ... Craig Dahlgren, a recognized expert in marine protected ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... There were many fires burning in eastern New South ... July 11. , At 03:35 UTC on July 11 ... when Aqua passed over eastern New South Wales (NSW), ... natural-color visible image of the region and spotted smoke ... by MODIS,s thermal bands, are outlined in red. , ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... large urban areas are at a significantly higher risk ... giving birth compared to those living in rural areas, ... College Hospital,s Dr. Simone Vigod. The study, ... , strongly links geographic location and postpartum depression. The ...
... and colleagues from Chengde Medical College have shown ... heme oxygenase-1 expression in the hippocampus and cerebral ... in diabetic rats, thus protecting the nervous system. ... growth factor 1 axis undergoes abnormal changes in ...
... Energy Department,s National Renewable Energy Laboratory (NREL) has published ... power plants based on actual land-use practices from existing ... of the solar plants in the United States will ... author Sean Ong said. The report, "Land-use Requirements for ...
Cached Biology News:Women in urban areas show high rates of postpartum depression, study finds 2NREL report firms up land-use requirements of solar 2
CELLine System cultivation flask (for secreted products)...
... StabilCoat Plus Microsphere/Microarray Stabilizer is an aqueous ... and other non-toxic chemicals in a PBS ... 7.4. This product contains a combination ... a preservative. StabilCoat Plus Stabilizer provides ...
... The mini incubation trays are ... to screen antigens that have ... Each tray has eight 10.5 ... that accommodate strips cut from ...
... designed for quick and easy protein purification ... two 0.25mm holes laser cut at the ... remain liquid-tight during incubation of the gel ... protein diffuses from the gel into the ...
Biology Products: